DOSAGE FORMS OF TISSUE KALLIKREIN 1

Provided are dosage forms of one or more tissue kallikrein-1 (KLK1) polypeptides which have a total KLK1 polypeptide dosage of about 0.1 µg/kg to about 10.0 µg/kg, including subcutaneous and intravenous dosage forms. Also provided are related devices and methods of use thereof, for example, for trea...

Full description

Saved in:
Bibliographic Details
Main Authors PAULS, Rick, VERDOORN, Todd
Format Patent
LanguageEnglish
French
Published 13.09.2018
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Provided are dosage forms of one or more tissue kallikrein-1 (KLK1) polypeptides which have a total KLK1 polypeptide dosage of about 0.1 µg/kg to about 10.0 µg/kg, including subcutaneous and intravenous dosage forms. Also provided are related devices and methods of use thereof, for example, for treating ischemic and hemorrhagic conditions. L'invention concerne des formes posologiques d'un ou plusieurs polypeptides de la kallicréine tissulaire 1 (KLK1), qui présentent une dose totale de polypeptides de KLK1 d'environ 0,1 µg/kg à environ 10,0 µg/kg, y compris les formes posologiques sous-cutanées et intraveineuses. L'invention concerne également des dispositifs associés et leurs procédés d'utilisation, par exemple pour le traitement de pathologies ischémiques et hémorragiques.
Bibliography:Application Number: WO2018US21749